Loading...
•
Jun 30
CryoPort Q2 2025 Earnings Report
Cryoport reported strong double-digit revenue growth across all Life Sciences Services streams and reaffirmed its full-year 2025 revenue guidance.
Key Takeaways
Cryoport delivered a strong second quarter in 2025, with total revenue increasing 14% year-over-year to $45.5 million. This growth was driven by significant increases in Life Sciences Services revenue (up 21%) and Life Sciences Products revenue (up 8%). The company also achieved a net income of $105.2 million, primarily due to the divestiture of its CRYOPDP business, and saw a meaningful improvement in adjusted EBITDA.
Total revenue from continuing operations increased 14% year-over-year to $45.5 million in Q2 2025.
Commercial Cell & Gene Therapy revenue grew 33% year-over-year to $8.7 million, supporting 18 commercial therapies.
Net income for Q2 2025 was $105.2 million, significantly boosted by a $117.4 million gain from the CRYOPDP divestiture.
Cryoport reaffirmed its full-year 2025 revenue guidance of $165 million to $172 million, reflecting confidence in continued growth.
CryoPort
CryoPort
CryoPort Revenue by Segment
Revenue by Segment
Life Sciences Services Revenue
CapyFin.comBioLogistics Solutions Revenue
CapyFin.comBioStorage/BioServices Revenue
CapyFin.comLife Sciences Products Revenue
CapyFin.com Forward Guidance
Cryoport reaffirmed its full-year 2025 revenue guidance, expecting total revenue from continuing operations to be between $165.0 million and $172.0 million, representing 5% to 10% year-over-year growth.
Positive Outlook
- Reaffirmed full-year 2025 revenue guidance indicates confidence in continued growth.
- Anticipates up to an additional twenty application filings for therapies during the remainder of 2025.
- Expects one new therapy approval and three additional approvals for label/geographic expansions in 2025.
- FDA's removal of REMS requirements for certain CAR-T cell immunotherapies is expected to increase patient access and accelerate commercial scaling.
- Strategic partnership with DHL Group is expected to enhance global biologistics capabilities and expand Life Sciences Services business.
Challenges Ahead
- Guidance is dependent on current business and expectations, which may be impacted by external factors.
- Potential risks from national economic factors and global macroeconomic and geopolitical environment.
- Possible challenges due to supply chain constraints and inflationary pressures.
- Uncertainties related to tariffs and other trade restrictions.
- Impact of foreign currency fluctuations could affect financial results.
Revenue & Expenses
Visualization of income flow from segment revenue to net income